Company Overview and News

 
News Live: Amit Shah appears in Guj HC as witness in Naroda Gam riot case

2017-09-18 moneycontrol
The United States seeks a peaceful resolution but is prepared to use military force if diplomatic efforts fail to end the nuclear standoff with North Korea, reports Bloomberg. “If our diplomatic efforts fail, though, our military option will be the only one left,” Secretary of State Rex Tillerson said. “But be clear: we seek a peaceful solution to this.” President Donald Trump, in a Sunday tweet, mocked North Korean leader Kim Jong Un as “Rocket Man.

 
News Live: Sikka loyalist Infosys Senior VP Sanjay Rajagopalan resigns

2017-09-18 moneycontrol
The United States seeks a peaceful resolution but is prepared to use military force if diplomatic efforts fail to end the nuclear standoff with North Korea, reports Bloomberg. “If our diplomatic efforts fail, though, our military option will be the only one left,” Secretary of State Rex Tillerson said. “But be clear: we seek a peaceful solution to this.” President Donald Trump, in a Sunday tweet, mocked North Korean leader Kim Jong Un as “Rocket Man.

 
News Live: India to replace China as growth engine

2017-09-18 moneycontrol
The United States seeks a peaceful resolution but is prepared to use military force if diplomatic efforts fail to end the nuclear standoff with North Korea, reports Bloomberg. “If our diplomatic efforts fail, though, our military option will be the only one left,” Secretary of State Rex Tillerson said. “But be clear: we seek a peaceful solution to this.” President Donald Trump, in a Sunday tweet, mocked North Korean leader Kim Jong Un as “Rocket Man.

 
News Live: Fosun to buy 74% in Gland Pharma for $1.1bn

2017-09-18 moneycontrol
China's Fosun Group has agreed to tweak its buyout deal with the promoters of Hyderabad-based Gland Pharma and acquire 74% of the company for USD 1.1 billion. This transaction had earlier been on hold for over a year due to regulatory hurdles. Last July, Shanghai Fosun had agreed to buy 86% of the generic injectables firm from its shareholders but was not cleared by the Cabinet Committee of Economic Affairs.

3
Shanghai Fosun to Buy Smaller Stake in Indian Drugmaker to Avoid Government Veto - Bloomberg

2017-09-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Two HNA deals hit hurdles as China tightens scrutiny: sources

2017-08-01 in.reuters
HONG KONG (Reuters) - At least two of HNA Group's overseas deals have hit a hurdle as the Chinese conglomerate struggles to take money out of China, said four people familiar with the process, amid a widening crackdown by Beijing on debt-fueled corporate acquisitions.

 
India likely to block $1.3 bn Gland Pharma-Fosun deal

2017-08-01 thehindubusinessline
India has privately raised objections to Chinese firm Shanghai Fosun Pharmaceutical Group's proposed $1.3 billion takeover of Indian drugmaker Gland Pharma, a source familiar with the matter said on Monday.

 
India raises concerns around Chinese firm Fosun#39;s takeover of Gland: Source

2017-08-01 moneycontrol
India has privately raised objections to Chinese firm Shanghai Fosun Pharmaceutical Group's proposed $1.3 billion takeover of Indian drugmaker Gland Pharma, a source familiar with the matter said on Monday.

 
UPDATE 1-India raises concerns around Chinese firm Fosun's takeover of Gland-source

2017-07-31 reuters
(Reuters) - India has privately raised objections to Chinese firm Shanghai Fosun Pharmaceutical Group's (600196.SS) proposed $1.3 billion takeover of Indian drugmaker Gland Pharma, a source familiar with the matter said on Monday.

 
India set to block $1.3 billion Gland Pharma-Fosun deal: Bloomberg

2017-07-31 in.reuters
(Reuters) - India's Cabinet Committee on Economic Affairs, chaired by Prime Minister Narendra Modi, has decided to block China's Shanghai Fosun Pharmaceutical Group Co's (600196.SS) proposed $1.3 billion takeover of Indian drugmaker Gland Pharma Ltd, Bloomberg reported, citing people familiar with the matter.

 
FIPB holds up Gland Pharmas acquisition by Chinese firm

2017-03-25 indiainfoline
The Foreign Investment and Promotion Board (FIPB) has postponed Gland Pharma’s deal with a Chinese firm, Shanghai Fosun, amounting to $1.4 billion.

 
FIPB Defers Gland Pharma's Acquisition by Chinese Firm

2017-03-24 business-standard
The Foreign Investment and Promotion Board (FIPB) has deferred the Gland Pharma-Shanghai Fosun deal worth $1.4 billion.

 
Big Deal: Know who's making news on Deal Street

2016-08-01 moneycontrol
Big Deal throws more light on large transactions that have been announced in India and overseas; a Chinese firm, Shanghai Fosun set to acquire 86 percent stake in Gland Pharma for over USD 1.3 billion; Yahoo sells its web business to Verizon for just under USD 5 billion and Flipkart's Myntra pips Snapdeal.

 
China's Fosun Just Paid $1.4 Billion for This KKR-Backed Company - Fortune

2016-07-29 fortune
Shanghai Fosun Pharmaceutical Group Co Ltd has agreed to buy Gland Pharma – backed by KKR & Co LP – for about $1.4 billion, a person with direct knowledge of the matter said, in India’s largest inbound acquisition this year.

 
Shanghai Fosun to pick 86% in Gland Pharma for $1.3 b

2016-07-28 thehindubusinessline
In one of the biggest acquisition by a Chinese company in India, Shanghai Fosun Pharmaceutical Group Co Ltd has agreed to buy 86 per cent in Gland Pharma for about $1.3 billion. Gland Pharma, backed by private equity firm KKR & Co LP, has a strong portfolio in injectable drugs. The deal overtakes investments made by Chinese e-commerce giant Alibaba in India’s booming online retail sector.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...